New drug trial targets rare, Hard-to-Treat cancer
NCT ID NCT07104331
Summary
This study is testing an intravenous drug called nab-sirolimus for adults with a rare cancer called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms and needs treatment. The main goal is to see if the drug can shrink tumors. Researchers will also track how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sloan Kettering Institute for Cancer Research
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
Stanford University
NOT_YET_RECRUITINGStanford, California, 94305, United States
-
University of Colorado
NOT_YET_RECRUITINGAurora, Colorado, 80203, United States
-
Washington University St. Louis
NOT_YET_RECRUITINGSt Louis, Missouri, 63130, United States
Conditions
Explore the condition pages connected to this study.